This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NVO Stock Rises on Upbeat Phase III Data for Cagrilintide in Obesity
by Zacks Equity Research
Novo Nordisk stock rises as its next-generation subcutaneous obesity treatment candidate, cagrilintide, delivers meaningful weight loss in a phase III obesity study.
AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?
by Sundeep Ganoria
Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.
Will Rybelsus' Updated EU Label Propel Fresh Growth Potential for NVO?
by Ahan Chakraborty
Novo Nordisk gains EU approval for adding the cardiovascular indication to Rybelsus' label, strengthening its edge in the competitive diabetes market.
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
Viking Therapeutics, Inc. (VKTX) reached $24.09 at the closing of the latest trading day, reflecting a -2.92% change compared to its last close.
Lilly Moves Past 50-Day SMA: Should You Consider Buying the Stock Now?
by Kinjel Shah
Eli Lilly shares move past the 50-day SMA as weight-loss drug data, rising sales and pipeline momentum fuel optimism.
Where Does VKTX Stock Stand After the Obesity Pill Setback?
by Sundeep Ganoria
Viking Therapeutics faces pressure after mixed oral obesity pill trial results, raising safety concerns but still meeting key study goals.
Is NVO's Major Restructuring Plan an Indication to Sell the Stock?
by Ahan Chakraborty
Novo Nordisk's sweeping restructuring plan cuts 9,000 jobs, targets DKK 8 billion in savings, and shifts focus to obesity and diabetes R&D.
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $25.48, indicating a -5.56% shift from the previous trading day.
Viking Therapeutics Loses 20% in a Month: How to Play the Stock
by Sundeep Ganoria
VKTX stock slumps after mixed obesity pill study results raise safety concerns and highlight fierce market competition.
NVO's Wegovy vs. LLY's Tirzepatide: Who Leads in Heart Risk Reduction?
by Ahan Chakraborty
Novo Nordisk's Wegovy shows a stronger reduction in heart risks compared to Eli Lilly's tirzepatide in real-world data from the STEER study.
Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
Viking Therapeutics, Inc. (VKTX) reached $27.05 at the closing of the latest trading day, reflecting a -1.92% change compared to its last close.
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet?
by Ahan Chakraborty
NVO and VKTX face setbacks and rising competition as they battle for ground in the GLP-1 obesity market.
Does Lilly's New Obesity Pill Data Put It Back in the Weight Game?
by Kinjel Shah
LLY's obesity pill orforglipron hits weight-loss and A1C goals in a phase III trial, lifting shares nearly 6% and reviving investor confidence.
Can Novo Nordisk Offset GLP-1 Pressures With Rare Disease Wins?
by Ahan Chakraborty
NVO faces slowing GLP-1 momentum but leans on rare disease wins and new Wegovy approval to bolster growth.
Viking Therapeutics (VKTX) Down 23.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Orforglipron Pill Setback End of the Road for LLY's Obesity Plans?
by Kinjel Shah
Lilly's obesity pill orforglipron disappointed with lower weight loss, but its broad late-stage pipeline keeps growth hopes alive.
Post Obesity Pill Results Reveal: Buy, Sell or Hold VKTX Stock?
by Sundeep Ganoria
Viking Therapeutics stock sinks after mixed results from its obesity pill trial, raising doubts over safety, tolerability and future prospects.
Viking Therapeutics' Stock Tanks on Mixed Data From Obesity Pill Study
by Zacks Equity Research
VKTX shares plunge after mixed obesity pill study data shows weight loss success but high dropout rates.
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
NVO Stock Up on FDA Nod for Wegovy in MASH: More Upside Ahead?
by Zacks Equity Research
Novo Nordisk surges as Wegovy secures FDA approval for MASH, marking a breakthrough in liver care and expanding its blockbuster reach.
Lilly Stock Down 5% This Month: Should You Buy the Dip?
by Kinjel Shah
Eli Lilly stock is down 5% this month despite strong Q2 results and raised guidance, as data from a study on the obesity pill orforglipron disappointed.
Will New CEO's Leadership Propel Novo Nordisk's Next Growth Wave?
by Ahan Chakraborty
Maziar Mike Doustdar takes office as NVO's new CEO, bringing a proven global growth record to tackle rising obesity market competition.
Novo Nordisk Rises 6% So Far in August: How to Play the Stock
by Ahan Chakraborty
NVO stock climbs nearly 6% in August as Lilly's oral obesity candidate setback pivots investor sentiment toward the former's advancing pipeline.
Can Eli Lilly Keep Up as NVO Eyes First Oral Obesity Pill Approval?
by Ahan Chakraborty
LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral obesity pill.